CDI, Including Epidemiology, Etiology, Pathophysiology, Symptoms, Diagnosis, and Current Management Strategies 2026

“Clostridium difficile Infections”
WiseGuyReports published new report, titled “OpportunityAnalyzer: Clostridium difficile Infections”


WiseGuyReports published new report, titled “OpportunityAnalyzer: Clostridium difficile Infections”

Clostridium difficile, a Gram-positive, spore-forming, toxin-producing, non-invasive, anaerobic bacterium, is the causative organism of C. difficile infection (CDI), which is commonly associated with colitis, as well as C. difficile-associated diarrhea (CDAD. CDIs begin with colonization of the intestinal tract with C. difficile through community-acquired or healthcare-associated means. Observed most frequently in healthcare settings, CDIs often occur when normal intestinal flora are disrupted by antibiotic administration, which can give C. difficile a competitive growth advantage if patients are exposed to the pathogen. Since 2000, CDIs have become more frequent, more severe, more difficult to treat using existing therapies, and more likely to recur than previously described. These realities, along with increasing threat of antibiotic resistance, underscore the importance of developing CDI-specific therapies and bringing them to market.

During the 10-year forecast period, there are nine products that are on track to launch, contributing to significant growth within the market. The launch of the first prophylactic options for the prevention of CDIs, beginning with Sanofi Pasteur’s vaccine ACAM-CDIFF in 2019, will fulfill a major unmet need, and will have a significant effect on the overall size of the CDI market. The expected launch of the first microbiologic therapies, leveraging the efficacy associated with FMT with respect to CDI recurrence rates, will also have an effect on the overall treatment landscape during the forecast period. In 2026, antibiotics are expected to have remained the highest grossing product class in the CDI market, with novel vaccines also contributing a significant market share.




– Overview of CDI, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies. 
– Topline CDI market revenue from 2016-2026. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included. 
– Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting CDI therapeutics and prophylactics sales in the 7MM. 
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. 
– Analysis of the current and future market competition in the global CDI therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.


Key points to buy

The report will enable you to – 

– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. 
– Develop business strategies by understanding the trends shaping and driving the global CDI therapeutics and prophylactics market. 
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CDI therapeutics and prophylactics market in the future. 
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


Table of Contents 

1 Table of Contents

2 Executive Summary 

3 Introduction 

4 Disease Overview

5 Epidemiology 

6 Current Treatment Options

7 Unmet Needs Assessment and Opportunity Analysis

8 Research and Development Strategies 

9 Pipeline Assessment

10 Pipeline Valuation Analysis 

11 Appendix 




About Us

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Media Contact
Company Name:
Contact Person: Norah Trent
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India